The Evolution of India's Pharmaceutical Export Traceability System: From DGFT Track & Trace to CDSCO-Led Serialization Compliance

Introduction

India is one of the world's largest pharmaceutical manufacturing and exporting nations, supplying medicines to more than 200 countries. With growing global concerns around counterfeit drugs, supply-chain security, patient safety, and regulatory transparency, pharmaceutical traceability systems became an essential component of international trade compliance.

To address these concerns, the Government of India introduced the 'Track and Trace' system for pharmaceutical exports in 2011 under the Directorate General of Foreign Trade (DGFT). The objective was to establish a serialization and barcode-based identification framework for exported pharmaceutical products. The system aimed to ensure authenticity, improve supply-chain visibility, and align Indian pharmaceutical exports with global standards.

For more than a decade, pharmaceutical exporters in India were required to comply with serialization norms, barcode requirements, and data-upload obligations through the DAVA (Drugs Authentication and Verification Application) portal. However, despite its ambitious goals, the system faced continuous implementation challenges, operational complexity, technological inconsistencies, and resistance from the industry.

In a major policy shift, the Government of India officially withdrew the DGFT Track & Trace provisions effective from 1 February 2025. The withdrawal marked the end of the DAVA-based export traceability regime. However, this did not eliminate pharmaceutical serialization or barcode compliance altogether. Instead, the regulatory ecosystem transitioned toward a more decentralized framework led by the Ministry of Health & Family Welfare (MoHFW), the Central Drugs Standard Control Organization (CDSCO), and importing-country regulations.

This article examines the evolution of India's pharmaceutical traceability framework, the rise and withdrawal of the Track & Trace system, the reasons behind the policy change, and the current compliance environment governing pharmaceutical exports.

Background of the Track & Trace System

Why the System Was Introduced

The pharmaceutical industry globally has long faced the challenge of counterfeit and substandard medicines entering legitimate supply chains. According to the World Health Organization (WHO), counterfeit drugs pose serious risks to public health, especially in developing economies.

India, being one of the world's largest exporters of generic medicines, came under increasing international scrutiny regarding supply-chain authenticity and product verification. Importing countries demanded stronger traceability mechanisms to identify:

• Product origin
• Manufacturing details
• Batch information
• Distribution channels
• Authenticity verification

In response, the Government of India introduced a mandatory Track & Trace mechanism in 2011 through DGFT notifications.

The system sought to:

• Enhance the credibility of Indian pharmaceutical exports
• Prevent counterfeiting
• Enable end-to-end product traceability
• Improve international confidence in Indian medicines
• Align exports with emerging global serialization standards

Structure of the Original Track & Trace System

Serialization and Barcode Requirements

The Track & Trace system introduced mandatory barcode and serialization requirements at multiple packaging levels.

These included:

1. Primary Packaging

The smallest saleable unit such as:

• Blister packs
• Bottles
• Strips
• Vials

2. Secondary Packaging

Intermediate packaging such as cartons.

3. Tertiary Packaging

Shipper cartons and export containers.

Each package level required unique identification codes.

GS1 Standards and DataMatrix Codes

The Indian pharmaceutical serialization framework adopted globally accepted GS1 standards.

The system primarily used:

• GS1 GTIN (Global Trade Item Number)
• Serialized identification numbers
• 2D DataMatrix barcodes
• Parent-child aggregation

Typical encoded information included:

• Product code
• Batch number
• Expiry date
• Manufacturing details
• Serial number

The barcode system allowed supply-chain participants to scan and verify products throughout the export journey.

The DAVA Portal

To operationalize Track & Trace, the Government established the DAVA (Drugs Authentication and Verification Application) portal.

The DAVA portal served as a centralized database where exporters uploaded serialization information for exported consignments.

Functions of DAVA included:

• Data repository management
• Product authentication
• Shipment verification
• Barcode data uploads
• Export tracking

Exporters were required to upload:

• Product serialization data
• Parent-child aggregation details
• Packaging hierarchy information
• Shipment records

The system was intended to create digital visibility for pharmaceutical exports.

Phased Implementation

The implementation occurred in phases.

Phase 1: Tertiary Packaging

Initially, barcode requirements applied only to tertiary packaging. This phase was relatively manageable because exporters could serialize outer shipping cartons without major production-line modifications.

Phase 2: Secondary Packaging

The government later extended serialization requirements to secondary packaging levels. Companies had to invest in:

• Barcode printers
• Vision inspection systems
• Aggregation software
• Serialization servers

Proposed Phase 3: Primary Packaging

Primary-level serialization was proposed later but repeatedly postponed because of technical and operational concerns.

The pharmaceutical industry argued that primary serialization:

• Increased production costs significantly
• Reduced manufacturing efficiency
• Created operational bottlenecks
• Was difficult for small and medium manufacturers

As a result, implementation deadlines were continuously extended.

Challenges Faced by the Track & Trace System

Although the Track & Trace framework was conceptually strong, implementation proved difficult.

1. Technological Complexity

Serialization requires sophisticated infrastructure including:

• High-speed printing systems
• Vision cameras
• Aggregation software
• Enterprise integration
• Real-time database management

Many small and medium pharmaceutical companies struggled to implement these systems effectively.

2. High Compliance Costs

Implementation costs were substantial.

Companies had to invest in:

• Serialization hardware
• Software licenses
• Production-line upgrades
• Maintenance contracts
• Data management infrastructure

For smaller exporters, compliance became financially burdensome.

3. Frequent Policy Extensions

The government repeatedly extended implementation deadlines for primary packaging and parent-child data uploads. This created uncertainty in the industry. Exporters often delayed investments because timelines kept changing.

4. Operational Difficulties

Manufacturers reported several operational challenges including:

• Production slowdowns
• Printing errors
• Data synchronization failures
• Aggregation mismatches
• DAVA upload issues

Many companies found the upload requirements cumbersome and inconsistent.

5. Duplication with International Requirements

One of the major criticisms of the DAVA framework was duplication.

Exporters already had to comply with serialization regulations of importing countries such as:

• US DSCSA
• EU Falsified Medicines Directive (FMD)
• Russia Chestny ZNAK
• Saudi Track & Trace systems
• UAE Tatmeen

As a result, companies often maintained multiple serialization systems simultaneously.

Industry stakeholders argued that the DGFT framework added an additional compliance layer without significant practical value.

Withdrawal of the Track & Trace System

Government Decision in 2025

On 31 January 2025, DGFT officially withdrew Para 2.76 of the Handbook of Procedures under the Foreign Trade Policy.

The withdrawal became effective from 1 February 2025.

This effectively ended:

• Mandatory DAVA uploads
• DGFT serialization obligations
• Parent-child upload requirements
• Export Track & Trace obligations under DGFT

The government acknowledged that:

• Most importing countries already had their own traceability systems
• Industry faced operational challenges
• Existing frameworks created duplication

The policy shift represented a major simplification of export compliance procedures.

What Replaced the Track & Trace System?

Importantly, the withdrawal of DGFT Track & Trace did not eliminate pharmaceutical traceability requirements altogether.

Instead, the compliance ecosystem shifted toward three major pillars:

1. CDSCO/MoHFW barcode regulations
2. Importing-country serialization laws
3. Global GS1 standards

CDSCO and MoHFW Barcode Compliance

Shift from Trade Regulation to Health Regulation

The responsibility for pharmaceutical authentication and traceability has gradually shifted from DGFT to health regulators.

The Ministry of Health & Family Welfare (MoHFW) and CDSCO now play a central role. Under the Drugs Rules, 1945, barcode and QR code requirements have become mandatory for selected pharmaceutical products.

QR Code Requirements for Drug Brands

India introduced QR code requirements for the top 300 pharmaceutical brands beginning 1 August 2023.

These QR codes contain:

• Product identification
• Batch details
• Expiry date
• Manufacturing information
• Serial numbers

Consumers and regulators can scan these codes to verify product authenticity.

This initiative aims to combat counterfeit medicines in the domestic market while improving traceability.

Focus on Consumer Authentication

Unlike the earlier DAVA export system, the newer barcode framework emphasizes:

• Consumer verification
• Product authentication
• Anti-counterfeit protection
• Domestic regulatory oversight

The approach is more health-regulatory in nature rather than export-administrative.

Country-Specific Serialization Compliance

Global Regulatory Environment

Today, pharmaceutical exporters primarily comply with importing-country regulations rather than a centralized Indian export portal.

Different countries maintain their own serialization frameworks.

United States: DSCSA

The US Drug Supply Chain Security Act (DSCSA) requires:

• Product serialization
• Transaction tracking
• Supply-chain verification
• Electronic interoperability

Indian exporters supplying the US market must comply fully with DSCSA obligations.

European Union: Falsified Medicines Directive

The EU FMD requires:

• Unique identifiers
• Tamper-evident packaging
• Centralized verification systems

Exporters must upload data to EU repositories before products enter the market.

Russia: Chestny ZNAK

Russia maintains one of the world's most complex pharmaceutical serialization systems.

Requirements include:

• Crypto-coded labels
• Real-time tracking
• Government database integration

Indian exporters to Russia must integrate directly with the Russian system.

Gulf Countries and Emerging Markets

Countries such as:

• Saudi Arabia
• UAE
• Bahrain
• Egypt

also maintain independent pharmaceutical traceability regulations. As a result, exporters increasingly adopt market-specific serialization strategies.

Continued Importance of GS1 Standards

Even though DAVA has been withdrawn, GS1 standards remain highly relevant. Most international serialization systems continue using:

• GTINs
• DataMatrix barcodes
• Serialized product identifiers
• Aggregation methodologies

Therefore, Indian pharmaceutical manufacturers continue investing in serialization infrastructure despite the end of DGFT requirements.

Industry Impact of the Withdrawal

Positive Outcomes

The withdrawal of the Track & Trace system produced several benefits.

Reduced Compliance Burden

Exporters no longer need to:

• Upload data to DAVA
• Maintain DGFT-specific reporting structures
• Handle duplicate serialization workflows

Lower Administrative Costs

Companies can streamline operations and focus on destination-country compliance.

Simplified Export Procedures

Export documentation and shipment processing became simpler.

Continuing Challenges

However, the withdrawal also presents certain challenges.

Lack of Centralized National Visibility

Without DAVA, India no longer has a centralized export serialization repository.

This may reduce:

• National-level traceability visibility
• Export analytics capability
• Unified anti-counterfeit oversight

Multiple Regulatory Systems

Exporters still face fragmented compliance obligations because each importing country has different requirements.

This creates:

• System complexity
• IT integration challenges
• Operational variability

Future of Pharmaceutical Traceability in India

India is unlikely to completely abandon serialization and traceability efforts.

Instead, the future appears focused on:

• Risk-based traceability
• Consumer-facing QR authentication
• International interoperability
• Health-regulatory oversight
• Digital supply-chain intelligence

Emerging technologies may also shape future systems including:

• Blockchain traceability
• AI-driven authentication
• Real-time supply-chain analytics
• Cloud-based serialization platforms

Strategic Implications for Exporters

Pharmaceutical exporters should now focus on:

• Destination-country regulatory compliance
• GS1-compatible serialization systems
• Flexible software architecture
• Scalable aggregation capabilities
• Digital supply-chain integration

Companies should also monitor evolving CDSCO regulations because domestic barcode requirements are expected to expand over time.

Conclusion

The withdrawal of India's DGFT Track & Trace system in 2025 marked the end of a significant chapter in pharmaceutical export regulation. Introduced in 2011 with the objective of improving traceability and combating counterfeit drugs, the system established mandatory serialization and barcode requirements for pharmaceutical exports through the DAVA platform.

Despite its strong policy intent, the framework faced persistent implementation challenges including high compliance costs, technological complexity, operational inefficiencies, and duplication with international regulations. Over time, global serialization systems evolved independently, reducing the practical necessity of a centralized Indian export-tracking portal.

The government's decision to withdraw the system reflects a broader shift toward decentralized and internationally aligned compliance models. Today, pharmaceutical traceability in India is governed through a combination of CDSCO barcode regulations, importing-country serialization laws, and globally accepted GS1 standards.

While the DAVA portal is no longer active, serialization itself remains highly relevant. Indian pharmaceutical exporters must continue investing in advanced traceability systems to satisfy international regulatory requirements and maintain global competitiveness.

The future of pharmaceutical traceability in India will likely emphasize interoperability, consumer authentication, digital health regulation, and global compliance integration rather than centralized export monitoring alone.

India's pharmaceutical industry now enters a new phase where traceability remains critical, but the mechanisms governing it have fundamentally evolved.

***